ArticleBlood advances2022
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.Frontiers in oncology · 2026Article
- Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.Blood advances · 2025Article
- Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions.Blood reviews · 2025Review
- Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.Blood cancer discovery · 2025Article
- Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.Annals of hematology · 2025Article
- EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.Cancer cell · 2025Article
- Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization.Frontiers in oncology · 2025Article
- Late complications and long-term care of adult CAR T-cell patients.Hematology. American Society of Hematology. Education Program · 2024Review
- Addressing platelet insecurity - A national call to action.Transfusion · 2024Article
- Article
- CAR-T Cell Therapy in Large B Cell Lymphoma.Mediterranean journal of hematology and infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 11 countries.
Ulrich JaegerDivision of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, and Comprehensive Cancer Center, Vienna, Austria.ORCID 0000-0001-9826-1062
Constantine S TamPeter MacCallum Cancer Center, and Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0002-9759-5017
Peter BorchmannClinic I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Joseph P McGuirkDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, University of Kansas, Kansas City, KS.ORCID 0000-0002-0539-4796
Marianne JohansenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Edmund K WallerBone Marrow and Stem Cell Transplant Center, Winship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0003-0816-6729
Samantha JaglowskiJames Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH.ORCID 0000-0002-4335-2554
Charalambos AndreadisHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-4681-6227
Stephen R FoleyDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Jason R WestinDepartment of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1824-2337
Isabelle FleuryMaisonneuve-Rosement Hospital, University of Montreal, Montreal, QC, Canada.
P Joy HoInstitute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia.
Stephan MielkeDepartment of Medicine II, University of Würzburg Medical Center, University of Würzburg, Würzburg, Germany.
Takanori TeshimaDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.ORCID 0000-0002-0941-271X
Gilles SallesMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9541-8666
Stephen J SchusterLymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-3376-8978
Fiona HeDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.
Richard T MaziarzCenter for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Sebastian MayerDivision of Hematology-Oncology, Bone Marrow and Stem Cell Transplantation Service, Weill Cornell Medicine, Cornell University, New York, NY.
Shinichi MakitaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-6609-8088
Marie J KerstenDepartment of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Monalisa GhoshBlood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.
Nina Wagner-JohnstonDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD.ORCID 0000-0001-6529-9793
Koji KatoDepartment of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Paolo CorradiniFondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.ORCID 0000-0002-9186-1353
Hideki GotoDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Silvia ColicinoNovartis Pharmaceuticals, Basel, Switzerland.
Abhijit AgarwalNovartis Pharmaceuticals, East Hanover, NJ; and.
Chiara Lobetti-BodoniNovartis Pharmaceuticals, Basel, Switzerland.
Michael R BishopHematopoietic Cellular Therapy Program, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
Hokkaido University Hospital · JPNovartis (Switzerland) · CHComprehensive Cancer Center Vienna · ATCornell University · USEmory University · USJohns Hopkins University · USKarolinska University Hospital · SEKyushu University Hospital · JPMcMaster University · CAMemorial Sloan Kettering Cancer Center · USOregon Health & Science University · USOslo University Hospital · NOThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Royal Melbourne Hospital · AUThe University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USTokyo National Hospital · JPUniversité de Montréal · CAUniversity Hospital Cologne · DEUniversity of Amsterdam · NL
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinHumansReceptors, Antigen, T-CellReceptors, Antigen, T-Celltisagenlecleucel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.